CEO Mark Goldsmith outlined the company’s late-stage plans for its RAS(ON) inhibitor daraxonrasib, discussed expansion into ...

Objective Cardiovascular diseases (CVD) remain the leading cause of mortality globally, necessitating early risk identification to improve prevention and management strategies. Traditional risk ...

This afternoon, we released financial results for the quarter and full year ended December 31, 2025, and recent corporate updates. The press release is available on the Investors section of our ...

Introduction Hypertension programmes have expanded substantially in low-income and middle-income countries, yet treatment and control rates remain insufficient. Programme scale-up may lead to ...

BACKGROUND: BCR-ABL tyrosine kinase inhibitors (TKIs) have been increasingly linked to pulmonary arterial hypertension (PAH) since 2009, although supporting evidence is limited. Our objective was to ...

A federal FOIA lawsuit, with a decision dated September 24, 2025, is forcing the release of internal CDC emails and spreadsheets that reveal how a disputed thimerosal study moved through agency review ...

Objectives To examine outcomes from respiratory pathogens containment strategies focused on international travellers. Design We developed a compartmental model generalisable to respiratory infectious ...